A Pilot Trial of Pioglitazone HCl and Tretinoin in ALS: Cerebrospinal Fluid Biomarkers to Monitor Drug Efficacy and Predict Rate of Disease Progression
Figure 2
Average pNFH levels in patients who lost <0.5 ALSFRS-R points per month compared to patients who lost >0.5 ALFRS-R points per month. (*Significant difference between the slow and fast progressors, by Mann-Whitney t-test). Error bars denote standard deviation.
